A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bayer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Stage IIIB (with effusion) or Stage IV NSCLC any histology
No prior chemotherapy
Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
Greater than or equal to 18 years of age
Life expectancy at least 12 weeks
Adequate bone marrow, liver and renal function
You may not be if
Prior systemic anti cancer therapy
Known brain metastasis. Patients with neurological symptoms should undergo at computed tomography (CT) scan/magnetic resonance imaging (MRI) of the brain to exclude brain metastasis
Pulmonary hemorrhage/bleeding event \> Common Terminology Criteria for Adverse Events (CTCAE) Grade 2 within 4 weeks of first dose of study drug
Thrombotic or embolic events including Transient ischemic attack (TIA) within the past 6 months
Uncontrolled hypertension
Any other hemorrhage/bleeding event \> CTCAE Grade 3 within 4 weeks of first dose of study drug
Major surgery within 4 weeks
Evidence or history of bleeding diathesis or coagulopathy
Clareo Health | A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC)
